Our product strategy is to develop critical need premium quality products to reach people in need of affordable treatments.
PHARMACARE PREMIUM’S current high potency solid dosage form products cover a range of hormonal analogues, oncology and immune-suppressants. The product line is being expanded through a pipeline of co-development projects, as well as through an in-licensing drive.
Additionally, and in association with RI Pharma, its wholly owned subsidiary in the UK, Pharmacare Premium intends to grow its range of conventional products. Pharmacare Premium’s products are at present finding markets in Europe, Latin America and MENA where we aim to develop a network of partner distributors.
Our Current Products (MAs in Malta, Portugal)